Persistent CD-19 depletion by rituximab is cost-effective in maintaining remission in calcineurin-inhibitor dependent podocytopathy. [electronic resource]
Producer: 20200430Description: 1241-1247 p. digitalISSN:- 1440-1797
- Adolescent
- Adult
- Antigens, CD19 -- analysis
- Calcineurin Inhibitors -- administration & dosage
- Costs and Cost Analysis
- Dose-Response Relationship, Drug
- Drug Monitoring -- methods
- Drug Resistance
- Female
- Glomerulosclerosis, Focal Segmental -- complications
- Glucocorticoids -- therapeutic use
- Humans
- Immunologic Factors -- administration & dosage
- India
- Male
- Nephrosis, Lipoid -- complications
- Nephrotic Syndrome -- drug therapy
- Rituximab -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Observational Study
There are no comments on this title.
Log in to your account to post a comment.